Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
ICAAC 2007: Chicago, Illinois; September 17-20, 2007

Key Links:

By Topic:

Search:

The 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
CHICAGO, ILLINOIS
SEPTEMBER 17-20, 2007


Conference Research Highlights

Featuring in-depth analysis from our team of expert faculty:

Calvin J. Cohen, M.D., M.S. Eric Daar, M.D. Edwin DeJesus, M.D. Benjamin Young, M.D., Ph.D.

About This Conference

The Body's coverage of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2007) includes a wide array of individual presentations and symposia, as well as summaries of some of the hottest topics in HIV research.

For more information on ICAAC 2007, please visit the conference's Web site.

Funding for coverage of this conference is provided, in part, by Abbott Laboratories, Boehringer Ingelheim and Tibotec Pharmaceuticals.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


multimedia from icaac
Podcasts & Interviews

Here's a sampling of our collection of ICAAC 2007 interviews:

Jay Lalezari, M.D., discusses the BOSS study, the first randomized study to examine the use of a needle-free device for the administration of enfuvirtide (T-20, Fuzeon).
Listen now
Read transcript

Ben Young, M.D., Ph.D., reviews his presentation, which analyzes the impact of tenofovir (TDF, Viread) on the kidney function of people who already have kidney disease.
Listen now
Read transcript

Pablo Tebas, M.D., discusses why people who stop taking HIV meds are potentially at a greater risk for cardiovascular disease than if they remain on treatment.
Listen now
Read transcript

More >>